Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 4351 AL 4365

Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors

Kordower JH, Burke RE.

Mov Disord. 2018 May;33(5):678-683. doi: 10.1002/mds.27383. Epub 2018 Mar 30.

New Imaging Markers for Movement Disorders

Ghadery C, Strafella AP.

Curr Neurol Neurosci Rep. 2018 Apr 3;18(5):22. doi: 10.1007/s11910-018-0830-x.

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease

Barrett MJ, Blair JC, Sperling SA, Smolkin ME, Druzgal TJ.

Neurology. 2018 May 1;90(18):e1618-e1626. doi: 10.1212/WNL.0000000000005421. Epub 2018 Apr 4.

Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials

Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B.

Mov Disord. 2018 Apr;33(4):528-536. doi: 10.1002/mds.27355.

Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease

Marsili L, Rizzo G, Colosimo C.

Front Neurol. 2018 Mar 23;9:156. doi: 10.3389/fneur.2018.00156. eCollection 2018.

Trazodone and Parkinsonism: The Link Strengthens

Sarwar AI.

Clin Neuropharmacol. 2018 May/Jun;41(3):106-108. doi: 10.1097/WNF.0000000000000278.

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

Lang AE, Espay AJ.

Mov Disord. 2018 May;33(5):660-677. doi: 10.1002/mds.27360. Epub 2018 Apr 11.

The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach

Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, Hatcher-Martin J, Mari Z, Moukheiber E, Okubadejo NU, Shalash A; International Parkinson and Movement Disorder Society Telemedicine Task Force.

Curr Neurol Neurosci Rep. 2018 Apr 13;18(5):26. doi: 10.1007/s11910-018-0834-6.

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study

Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C.

Mov Disord. 2018 Jul;33(6):960-965. doi: 10.1002/mds.27272. Epub 2018 Apr 17.

Insights into Parkinson's disease from computational models of the basal ganglia

Humphries MD, Obeso JA, Dreyer JK.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1181-1188. doi: 10.1136/jnnp-2017-315922. Epub 2018 Apr 17.

Quantifying Motor Impairment in Movement Disorders

FitzGerald JJ, Lu Z, Jareonsettasin P, Antoniades CA.

Front Neurosci. 2018 Apr 11;12:202. doi: 10.3389/fnins.2018.00202. eCollection 2018.

Cost-Minimization Analysis of Deep-Brain Stimulation Using National Database of Japanese Health Insurance Claims

Akazawa M, Konomura K, Shiroiwa T.

Neuromodulation. 2018 Aug;21(6):548-552. doi: 10.1111/ner.12782. Epub 2018 Apr 26.

Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial

Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng WY, Fernandez-Garcia I, Siebourg-Polster J, Jin L, Soto J, Verselis L, Boess F, Koller M, Grundman M, Monsch AU, Postuma RB, Ghosh A, Kremer T, Czech C, Gossens C, Lindemann M.

Mov Disord. 2018 Aug;33(8):1287-1297. doi: 10.1002/mds.27376. Epub 2018 Apr 27.

On the neuronal circuitry mediating L-DOPA-induced dyskinesia

Cenci MA, Jörntell H, Petersson P.

J Neural Transm (Vienna). 2018 Aug;125(8):1157-1169. doi: 10.1007/s00702-018-1886-0. Epub 2018 Apr 27.

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

Sardi SP, Cedarbaum JM, Brundin P.

Mov Disord. 2018 May;33(5):684-696. doi: 10.1002/mds.27414. Epub 2018 Apr 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias